Market Analysis
The global Long-Acting Monoclonal Antibodies Market was valued at USD 18.6 billion in 2024 and is projected to reach USD 52.4 billion by 2032, expanding at a CAGR of 16.3% from 2025 to 2032.
This exponential growth is fueled by increasing adoption of biologics, rising prevalence of chronic diseases, and continuous innovations in antibody engineering.
